Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper
Reaktivität: Human
FACS, ELISA, BLI, Func, SPR
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle MS4A1 (Rituximab Biosimilar) Produkte
- MS4A1 (Rituximab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
-
Reaktivität
- Human
-
Wirt
-
Human
- Expressionssystem
- CHO Cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser MS4A1 (Rituximab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- Flow Cytometry (FACS), ELISA, Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
- Verwendungszweck
- Anti-CD20 / MS4A1 Reference Antibody (rituximab)
- Sequenz
- QVQLQQPGAE LVKPGASVKM SCKASGYTFT SYNMHWVKQT PGRGLEWIGA IYPGNGDTSY NQKFKGKATL TADKSSSTAY MQLSSLTSED SAVYYCARST YYGGDWYFNV WGAGTTVTVS AASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKAE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K,QIVLSQSPAI LSASPGEKVT MTCRASSSVS YIHWFQQKPG SSPKPWIYAT SNLASGVPVR FSGSGSGTSY SLTISRVEAE DAATYYCQQW TSNPPTFGGG TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
- Produktmerkmale
- Anti-CD20 Reference Antibody (rituximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 146.32 kDa.
- Reinheit
- >95 %
- Isotyp
- IgG1
-
anti-MS4A1 (Rituximab Biosimilar) antibody
Reaktivität: Human, Cynomolgus, Rhesusaffen FACS Wirt: Kaninchen Chimeric 10F381 unconjugated Recombinant Antibody
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Therapeutic Agents by Target and Mechanism: CD20 inhibitors(B lymphocyte antigen CD20 inhibitors), ADCC(antibody-dependent cytotoxicity), CD20(targeted cytolysis)
Conditions: Chronic Lymphocytic Leukemia Non-Hodgkin's Lymphoma Rheumatoid Arthritis (Anti-TNF Refractory) Vasculitis ANCA-associated
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- +4°C,-80°C
-
- Target
- MS4A1 (Rituximab Biosimilar)
- Andere Bezeichnung
- CD20 (Rituximab Biosimilar) (MS4A1 (Rituximab Biosimilar) Produkte)
- Substanzklasse
- Biosimilar
- Hintergrund
- Synonyms: Membrane-spanning 4-domains, subfamily A, member 1, MS4A1, B lymphocyte surface antigen B1, Leu-16, Bp35
- Molekulargewicht
- 146.32 kDa
- UniProt
- P11836
-
Sie sind hier:
